{"pmid":32471205,"title":"Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.","text":["Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.","Since the outbreak of the COVID-19 pandemic in December 2019 and its rapid spread worldwide, the scientific community has been under pressure to react and make progress in the development of an effective treatment against the virus responsible for the disease. Here, we implement an original virtual screening (VS) protocol for repositioning approved drugs in order to predict which of them could inhibit the main protease of the virus (M-pro), a key target for antiviral drugs given its essential role in the virus' replication. Two different libraries of approved drugs were docked against the structure of M-pro using Glide, FRED and AutoDock Vina, and only the equivalent high affinity binding modes predicted simultaneously by the three docking programs were considered to correspond to bioactive poses. In this way, we took advantage of the three sampling algorithms to generate hypothetic binding modes without relying on a single scoring function to rank the results. Seven possible SARS-CoV-2 M-pro inhibitors were predicted using this approach: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 microM, respectively.","Int J Mol Sci","Gimeno, Aleix","Mestres-Truyol, Julia","Ojeda-Montes, Maria Jose","Macip, Guillem","Saldivar-Espinoza, Bryan","Cereto-Massague, Adria","Pujadas, Gerard","Garcia-Vallve, Santiago","32471205"],"abstract":["Since the outbreak of the COVID-19 pandemic in December 2019 and its rapid spread worldwide, the scientific community has been under pressure to react and make progress in the development of an effective treatment against the virus responsible for the disease. Here, we implement an original virtual screening (VS) protocol for repositioning approved drugs in order to predict which of them could inhibit the main protease of the virus (M-pro), a key target for antiviral drugs given its essential role in the virus' replication. Two different libraries of approved drugs were docked against the structure of M-pro using Glide, FRED and AutoDock Vina, and only the equivalent high affinity binding modes predicted simultaneously by the three docking programs were considered to correspond to bioactive poses. In this way, we took advantage of the three sampling algorithms to generate hypothetic binding modes without relying on a single scoring function to rank the results. Seven possible SARS-CoV-2 M-pro inhibitors were predicted using this approach: Perampanel, Carprofen, Celecoxib, Alprazolam, Trovafloxacin, Sarafloxacin and ethyl biscoumacetate. Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3.97 and 11.90% M-pro inhibition at 50 microM, respectively."],"journal":"Int J Mol Sci","authors":["Gimeno, Aleix","Mestres-Truyol, Julia","Ojeda-Montes, Maria Jose","Macip, Guillem","Saldivar-Espinoza, Bryan","Cereto-Massague, Adria","Pujadas, Gerard","Garcia-Vallve, Santiago"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471205","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113793","keywords":["2019-ncov","3cl-pro","covid-19","m-pro","sars coronavirus","sars-cov-2","chymotrypsin-like protease"],"locations":["FRED","Perampanel","Carprofen","Trovafloxacin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193348702208,"score":9.490897,"similar":[{"pmid":32374074,"title":"Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.","text":["Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease.","A novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], or 2019 novel coronavirus [2019-nCoV]) has been identified as the pathogen of coronavirus disease 2019 (COVID-19). The main protease (M(pro) , also called 3-chymotrypsin-like protease [3CL(pro) ]) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M(pro) homodimer structure suitable for docking simulations was prepared using a crystal structure (PDB ID: 6Y2G; resolution 2.20 A). Structural refinement was performed in the presence of peptidomimetic alpha-ketoamide inhibitors, which were previously disconnected from each Cys145 of the M(pro) homodimer, and energy calculations were performed. Structure-based virtual screenings were performed using the ChEMBL database. Through a total of 1,485,144 screenings, 64 potential drugs (11 approved, 14 clinical, and 39 preclinical drugs) were predicted to show high binding affinity with M(pro) . Additional docking simulations for predicted compounds with high binding affinity with M(pro) suggested that 28 bioactive compounds may have potential as effective anti-SARS-CoV-2 drug candidates. The procedure used in this study is a possible strategy for discovering anti-SARS-CoV-2 drugs from drug libraries that may significantly shorten the clinical development period with regard to drug repositioning.","FEBS Open Bio","Tsuji, Motonori","32374074"],"abstract":["A novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], or 2019 novel coronavirus [2019-nCoV]) has been identified as the pathogen of coronavirus disease 2019 (COVID-19). The main protease (M(pro) , also called 3-chymotrypsin-like protease [3CL(pro) ]) of SARS-CoV-2 is a potential target for treatment of COVID-19. A M(pro) homodimer structure suitable for docking simulations was prepared using a crystal structure (PDB ID: 6Y2G; resolution 2.20 A). Structural refinement was performed in the presence of peptidomimetic alpha-ketoamide inhibitors, which were previously disconnected from each Cys145 of the M(pro) homodimer, and energy calculations were performed. Structure-based virtual screenings were performed using the ChEMBL database. Through a total of 1,485,144 screenings, 64 potential drugs (11 approved, 14 clinical, and 39 preclinical drugs) were predicted to show high binding affinity with M(pro) . Additional docking simulations for predicted compounds with high binding affinity with M(pro) suggested that 28 bioactive compounds may have potential as effective anti-SARS-CoV-2 drug candidates. The procedure used in this study is a possible strategy for discovering anti-SARS-CoV-2 drugs from drug libraries that may significantly shorten the clinical development period with regard to drug repositioning."],"journal":"FEBS Open Bio","authors":["Tsuji, Motonori"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374074","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/2211-5463.12875","keywords":["2019-ncov","covid-19","drug repositioning","mpro","sars-cov-2","virtual screening"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496321978368,"score":414.40024},{"pmid":32455534,"title":"Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.","text":["Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.","The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China followed by its spread around the world poses a serious global concern for public health. To this date, no specific drugs or vaccines are available to treat SARS-CoV-2 despite its close relation to the SARS-CoV virus that caused a similar epidemic in 2003. Thus, there remains an urgent need for the identification and development of specific antiviral therapeutics against SARS-CoV-2. To conquer viral infections, the inhibition of proteases essential for proteolytic processing of viral polyproteins is a conventional therapeutic strategy. In order to find novel inhibitors, we computationally screened a compound library of over 606 million compounds for binding at the recently solved crystal structure of the main protease (M(pro)) of SARS-CoV-2. A screening of such a vast chemical space for SARS-CoV-2 M(pro) inhibitors has not been reported before. After shape screening, two docking protocols were applied followed by the determination of molecular descriptors relevant for pharmacokinetics to narrow down the number of initial hits. Next, molecular dynamics simulations were conducted to validate the stability of docked binding modes and comprehensively quantify ligand binding energies. After evaluation of potential off-target binding, we report a list of 12 purchasable compounds, with binding affinity to the target protease that is predicted to be more favorable than that of the cocrystallized peptidomimetic compound. In order to quickly advise ongoing therapeutic intervention for patients, we evaluated approved antiviral drugs and other protease inhibitors to provide a list of nine compounds for drug repurposing. Furthermore, we identified the natural compounds (-)-taxifolin and rhamnetin as potential inhibitors of M(pro). Rhamnetin is already commercially available in pharmacies.","Int J Mol Sci","Fischer, Andre","Sellner, Manuel","Neranjan, Santhosh","Smiesko, Martin","Lill, Markus A","32455534"],"abstract":["The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China followed by its spread around the world poses a serious global concern for public health. To this date, no specific drugs or vaccines are available to treat SARS-CoV-2 despite its close relation to the SARS-CoV virus that caused a similar epidemic in 2003. Thus, there remains an urgent need for the identification and development of specific antiviral therapeutics against SARS-CoV-2. To conquer viral infections, the inhibition of proteases essential for proteolytic processing of viral polyproteins is a conventional therapeutic strategy. In order to find novel inhibitors, we computationally screened a compound library of over 606 million compounds for binding at the recently solved crystal structure of the main protease (M(pro)) of SARS-CoV-2. A screening of such a vast chemical space for SARS-CoV-2 M(pro) inhibitors has not been reported before. After shape screening, two docking protocols were applied followed by the determination of molecular descriptors relevant for pharmacokinetics to narrow down the number of initial hits. Next, molecular dynamics simulations were conducted to validate the stability of docked binding modes and comprehensively quantify ligand binding energies. After evaluation of potential off-target binding, we report a list of 12 purchasable compounds, with binding affinity to the target protease that is predicted to be more favorable than that of the cocrystallized peptidomimetic compound. In order to quickly advise ongoing therapeutic intervention for patients, we evaluated approved antiviral drugs and other protease inhibitors to provide a list of nine compounds for drug repurposing. Furthermore, we identified the natural compounds (-)-taxifolin and rhamnetin as potential inhibitors of M(pro). Rhamnetin is already commercially available in pharmacies."],"journal":"Int J Mol Sci","authors":["Fischer, Andre","Sellner, Manuel","Neranjan, Santhosh","Smiesko, Martin","Lill, Markus A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32455534","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21103626","keywords":["sars-2-cov","computational chemistry","coronavirus","virtual screening"],"locations":["China","quantify ligand"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["rhamnetin","taxifolin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698913460224,"score":359.45786},{"pmid":32486229,"title":"Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.","text":["Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.","The novel coronavirus, COVID-19, caused by SARS-CoV-2, is a global health pandemic that started in December 2019. The effective drug target among coronaviruses is the main protease M(pro), because of its essential role in processing the polyproteins that are translated from the viral RNA. In this study, the bioactivity of some selected heterocyclic drugs named Favipiravir (1), Amodiaquine (2), 2'-Fluoro-2'-deoxycytidine (3), and Ribavirin (4) was evaluated as inhibitors and nucleotide analogues for COVID-19 using computational modeling strategies. The density functional theory (DFT) calculations were performed to estimate the thermal parameters, dipole moment, polarizability, and molecular electrostatic potential of the present drugs; additionally, Mulliken atomic charges of the drugs as well as the chemical reactivity descriptors were investigated. The nominated drugs were docked on SARS-CoV-2 main protease (PDB: 6LU7) to evaluate the binding affinity of these drugs. Besides, the computations data of DFT the docking simulation studies was predicted that the Amodiaquine (2) has the least binding energy (-7.77 Kcal/mol) and might serve as a good inhibitor to SARS-CoV-2 comparable with the approved medicines, hydroxychloroquine, and remdesivir which have binding affinity -6.06 and -4.96 Kcal/mol, respectively. The high binding affinity of 2 was attributed to the presence of three hydrogen bonds along with different hydrophobic interactions between the drug and the critical amino acids residues of the receptor. Finally, the estimated molecular electrostatic potential results by DFT were used to illustrate the molecular docking findings. The DFT calculations showed that drug 2 has the highest of lying HOMO, electrophilicity index, basicity, and dipole moment. All these parameters could share with different extent to significantly affect the binding affinity of these drugs with the active protein sites.","Int J Mol Sci","Hagar, Mohamed","Ahmed, Hoda A","Aljohani, Ghadah","Alhaddad, Omaima A","32486229"],"abstract":["The novel coronavirus, COVID-19, caused by SARS-CoV-2, is a global health pandemic that started in December 2019. The effective drug target among coronaviruses is the main protease M(pro), because of its essential role in processing the polyproteins that are translated from the viral RNA. In this study, the bioactivity of some selected heterocyclic drugs named Favipiravir (1), Amodiaquine (2), 2'-Fluoro-2'-deoxycytidine (3), and Ribavirin (4) was evaluated as inhibitors and nucleotide analogues for COVID-19 using computational modeling strategies. The density functional theory (DFT) calculations were performed to estimate the thermal parameters, dipole moment, polarizability, and molecular electrostatic potential of the present drugs; additionally, Mulliken atomic charges of the drugs as well as the chemical reactivity descriptors were investigated. The nominated drugs were docked on SARS-CoV-2 main protease (PDB: 6LU7) to evaluate the binding affinity of these drugs. Besides, the computations data of DFT the docking simulation studies was predicted that the Amodiaquine (2) has the least binding energy (-7.77 Kcal/mol) and might serve as a good inhibitor to SARS-CoV-2 comparable with the approved medicines, hydroxychloroquine, and remdesivir which have binding affinity -6.06 and -4.96 Kcal/mol, respectively. The high binding affinity of 2 was attributed to the presence of three hydrogen bonds along with different hydrophobic interactions between the drug and the critical amino acids residues of the receptor. Finally, the estimated molecular electrostatic potential results by DFT were used to illustrate the molecular docking findings. The DFT calculations showed that drug 2 has the highest of lying HOMO, electrophilicity index, basicity, and dipole moment. All these parameters could share with different extent to significantly affect the binding affinity of these drugs with the active protein sites."],"journal":"Int J Mol Sci","authors":["Hagar, Mohamed","Ahmed, Hoda A","Aljohani, Ghadah","Alhaddad, Omaima A"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486229","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/ijms21113922","keywords":["covid 19","dft calculations","n-heterocycles","hydroxychloroquine","molecular docking"],"locations":["Amodiaquine"],"e_drugs":["2'-fluoro-2'-deoxycytidine","favipiravir","remdesivir","Amodiaquine","Hydroxychloroquine","Ribavirin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668623433677668352,"score":323.8741},{"pmid":32367767,"title":"Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.","text":["Potential Inhibitors of Coronavirus 3-Chymotrypsin-Like Protease (3CL(pro)): An in silico screening of Alkaloids and Terpenoids from African medicinal plants.","The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic.","J Biomol Struct Dyn","Gyebi, Gideon A","Ogunro, Olalekan B","Adegunloye, Adegbenro P","Ogunyemi, Oludare M","Afolabi, Saheed O","32367767"],"abstract":["The novel coronavirus disease 2019 (COVID-19) caused by SARS-COV-2 has raised myriad of global concerns. There is currently no FDA approved antiviral strategy to alleviate the disease burden. The conserved 3-chymotrypsin-like protease (3CL(pro)), which controls coronavirus replication is a promising drug target for combating the coronavirus infection. This study screens some African plants derived alkaloids and terpenoids as potential inhibitors of coronavirus 3CL(pro) using in silico approach.Bioactive alkaloids (62) and terpenoids (100) of plants native to Africa were docked to the 3CL(pro) of the novel SARS-CoV-2. The top twenty alkaloids and terpenoids with high binding affinities to the SARS-CoV-2 3CL(pro) were further docked to the 3CL(pro) of SARS-CoV and MERS-CoV. The docking scores were compared with 3CL(pro)-referenced inhibitors (Lopinavir and Ritonavir). The top docked compounds were further subjected to ADEM/Tox and Lipinski filtering analyses for drug-likeness prediction analysis.This ligand-protein interaction study revealed that more than half of the top twenty alkaloids and terpenoids interacted favourably with the coronaviruses 3CL(pro), and had binding affinities that surpassed that of lopinavir and ritonavir. Also, a highly defined hit-list of seven compounds (10-Hydroxyusambarensine, Cryptoquindoline, 6-Oxoisoiguesterin, 22-Hydroxyhopan-3-one, Cryptospirolepine, Isoiguesterin and 20-Epibryonolic acid) were identified. Furthermore, four non-toxic, druggable plant derived alkaloids (10-Hydroxyusambarensine, and Cryptoquindoline) and terpenoids (6-Oxoisoiguesterin and 22-Hydroxyhopan-3-one), that bind to the receptor-binding site and catalytic dyad of SARS-CoV-2 3CL(pro) were identified from the predictive ADME/tox and Lipinski filter analysis. However, further experimental analyses are required for developing these possible leads into natural anti-COVID-19 therapeutic agents for combating the pandemic."],"journal":"J Biomol Struct Dyn","authors":["Gyebi, Gideon A","Ogunro, Olalekan B","Adegunloye, Adegbenro P","Ogunyemi, Oludare M","Afolabi, Saheed O"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367767","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1764868","keywords":["covid-19","coronavirus 3clpro","molecular docking","natural product","sars-cov-2"],"locations":["Cryptoquindoline","Cryptospirolepine","Isoiguesterin"],"e_drugs":["10'-hydroxyusambarensine","Lopinavir","Ritonavir","Alkaloids","iguesterin","cryptospirolepine","20-epibryonolic acid","Terpenes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496156303362,"score":312.51523},{"pmid":32313296,"pmcid":"PMC7165110","title":"Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling.","text":["Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling.","We have applied a computational strategy, using a combination of virtual screening, docking and molecular dynamics techniques, aimed at identifying possible lead compounds for the non-covalent inhibition of the main protease 3CL(pro) of the SARS-CoV2 Coronavirus. Based on the X-ray structure (PDB code: 6LU7), ligands were generated using a multimodal structure-based design and then docked to the monomer in the active state. Docking calculations show that ligand-binding is strikingly similar in SARS-CoV and SARS-CoV2 main proteases. The most potent docked ligands are found to share a common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement.","Chem Phys Lett","Macchiagodena, Marina","Pagliai, Marco","Procacci, Piero","32313296"],"abstract":["We have applied a computational strategy, using a combination of virtual screening, docking and molecular dynamics techniques, aimed at identifying possible lead compounds for the non-covalent inhibition of the main protease 3CL(pro) of the SARS-CoV2 Coronavirus. Based on the X-ray structure (PDB code: 6LU7), ligands were generated using a multimodal structure-based design and then docked to the monomer in the active state. Docking calculations show that ligand-binding is strikingly similar in SARS-CoV and SARS-CoV2 main proteases. The most potent docked ligands are found to share a common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement."],"journal":"Chem Phys Lett","authors":["Macchiagodena, Marina","Pagliai, Marco","Procacci, Piero"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313296","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cplett.2020.137489","keywords":["3cl-pro","3cl-pro inhibitor","binding affinity","covid-19","coronavirus","coronavirus main protease","molecular docking","molecular dynamics","sars-cov2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493564223489,"score":307.02005}]}